Combining High-Throughput, High-Resolution Targeted Spatial Microdissection with SLIMamp® NGS Chemistry for Sensitive and Accurate Molecular Characterization on Low-Quantity, Low-Quality FFPE Samples
Pillar, QuantumCyte and AstraZeneca tested whether AI-guided spatial microdissection can rescue FFPE samples that would otherwise fail NGS. QuantumCyte's QCPRECISE!™ platform uses digital pathology to annotate slides and a printed mask to remove unwanted regions, extracting DNA from selectively lysed tumor cells in 2 mm tissue microarray cores taken from 31 samples previously characterized on Pillar's oncoReveal® HRD and BRCA1 & RAD51C methylation panels. Libraries were sequenced on the NextSeq 550 and analyzed in PiVAT®. Variants were called on all 31 samples with no cross-contamination, and 76% of evaluable samples matched known variant allele frequencies at 0.93 correlation.
